Please assess the completion status of the following clinical trial:

Trial Title: Interest of Contact Precautions for Preventing Micro-organisms Acquisition in Patients Hospitalized in Infectious Disease Unit of University-affiliated Hospital in Rennes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized in Infectious Diseases Unit during the study period in one of the selected part of the unit participating to the study~* Patient informed about the study protocol and approved to participate.~Exclusion Criteria:~* Patient requiring isolation prescription type air or droplet~* Patient hospitalized in the central sector of the building (including 4 bedrooms in depression negative service)~* Patient colonized with bacteria producing carbapenemase, multi-resistant Acinetobacter baumanii or Vancomycin-Resistant Enterococcus.~* Patients under legal protection (juridical protection, legal guardianship) or persons on juridical detention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard precautions (Type: None): One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design).
- contact precautions (Type: None): One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design).

Based on this trial design, predict the completion outcome and termination type (if applicable).